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Abstract
Purpose: Many planning methods for high dose rate (HDR) brachytherapy treatment planning require
an iterative approach. A set of computational parameters are hypothesized that will give a dose plan that
meets dosimetric criteria. A dose plan is computed using these parameters, and if any dosimetric criteria
are not met, the process is iterated until a suitable dose plan is found. In this way, the dose distribution is
controlled by abstract parameters. The purpose of this study is to improve HDR brachytherapy planning
by developing a new approach that directly optimizes the dose distribution based on dosimetric criteria.
Method: We develop Inverse Planning by Integer Program (IPIP), an optimization model for computing
HDR brachytherapy dose plans and a fast heuristic for it. We used our heuristic to compute dose plans
for 20 anonymized prostate cancer patient image data sets from our clinic database. Dosimetry was
evaluated and compared to dosimetric criteria.
Results: Dose plans computed from IPIP satisfied all given dosimetric criteria for the target and healthy
tissue after a single iteration. The average target coverage was 95%. The average computation time for
IPIP was 30.1 seconds on a Intel(R) CoreTM2 Duo CPU 1.67 GHz processor with 3 Gib RAM.
Conclusion: IPIP is an HDR brachytherapy planning system that directly incorporates dosimetric crite-
ria. We have demonstrated that IPIP has clinically acceptable performance for the prostate cases and
dosimetric criteria used in this study, both in terms of dosimetry and runtime. Further study is required
to determine if IPIP performs well for a more general group of patients and dosimetric criteria, including
other cancer sites such as GYN.
1 Introduction1
High dose rate (HDR) brachytherapy is a radiation therapy for cancer. In HDR brachytherapy, radiation is2
delivered directly to the tumor site via a moving radioactive source in temporarily inserted catheters. Dose3
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is controlled by altering the dwell times, the time spent at points along the catheters. Studies have shown4
that brachytherapy is a highly effective treatment [1, 2, 3, 4, 5, 6, 7, 8].5
Inverse planning explicitly uses anatomical information and dwell positions when computing HDR brachyther-6
apy dose plans. Clinical experience with HDR brachytherapy has led to organ doses that are correlated with7
biologically acceptable results [9], more specifically, the eradication of the tumor with reasonable side effects8
to healthy tissue. Recently, these organ doses have become the dosimetric criteria that form the objective of9
many dose planning systems.10
Many planning systems provide tools to quickly evaluate dose distributions and guide the user toward11
a final dose plan. However, finding a suitable dose plan may take several attempts. During dose planning,12
a set of computational parameters are hypothesized that will give a suitable dose plan (i.e. one that meets13
all dosimetric criteria). A dose plan is computed using these parameters, and if any dosimetric criteria14
are not met, the process is repeated until a suitable plan is found. In this way, the dose distribution is15
controlled by abstract parameters. The purpose of this study is to develop an inverse planning method for16
HDR brachytherapy that directly controls the dose distribution through dosimetric indices.17
We formulate HDR dose planning as an optimization model known as a mixed integer program. A mixed18
integer program is an optimization model where some or all of the variables are restricted to taking on19
integer values. Dosimetric criteria can be directly incorporated into our model using integer programming20
constraints. Since the constraints in mixed integer programs are hard constraints, our model is guaranteed21
to meet the given dosimetric criteria if physically possible; it will be declared infeasible otherwise. However,22
many integer programs are difficult to solve in a reasonable amount of time [10]. This is the case for our23
model, and in our initial tests, reasonably sized instances of our model did not provide an optimal solution,24
even given several hours.25
HDR brachytherapy is an outpatient procedure. Catheters are inserted, a dose plan computed and26
delivered, and the catheters removed in the course of about one day. As a consequence, an HDR brachytherapy27
planning system must be able to compute a dose plan within several minutes to not interrupt clinical workflow.28
Since our model does not meet this runtime restriction, we develop a heuristic that does.29
Although our heuristic converges to a solution quickly, it has three major limitations. First, as in all30
heuristic approaches, our heuristic is not guaranteed to compute an optimal solution for our model. Second,31
our heuristic is only guaranteed to comply with certain types of dosimetric criteria. Finally, within dosimetric32
criteria, our heuristic tends overdose healthy tissue, even for only small improvements to tumor dosing.33
Despite these limitations, we show that our heuristic approach can compute dose plans quickly, and for34
our patient cases, did not require any iterations beyond the first. Also, contrary to current approaches,35
if all dosimetric criteria are not met, physicians can iterate using different dosimetric criteria rather than36
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computational parameters. A comparison of the workflow between the current approach and our approach37
is shown in Figure 1.38
Figure 1: Clinical workflow for current approach (left) and our approach (right). With current approaches,
physicians iterate through dosimetric criteria and parameters. In our approach, iterations are only done using
dosimetric criteria.
Although our model can be used for any brachytherapy cancer site where dosimetric criteria is known or39
desired, for this study we focus on the treatment of prostate cancer. In the following section, we give some40
background on inverse planning and integer programs.41
2 Background42
In HDR brachytherapy, the tumor site is referred to as the clinical target volume (CTV), and surrounding43
healthy organs are referred to as organs at risk (OAR). A physician prescribes a dose, Rx [Gy], that should44
be delivered to as much of the CTV as possible, subject to constraints on the OAR. The dose delivered to an45
entire organ is quantified by dosimetric indices. For example, the VProstate100 is the prostate volume receiving46
at least 100% Rx.47
In inverse planning, organ volume is discretized into dose points. The dose received at the dose point is48
considered representative of the dose received in the near vicinity of the dose point. If dose points are evenly49
spaced, then a dosimetric index can be computed as the sum of all the dose points receiving over the dose50
threshold times the volume that a single dose point represents.51
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Clinical experience has determined ranges for dosimetric index values that are correlated with acceptable52
biological outcomes such as non-recurrence and minimal side effects to OAR. These dosimetric indices and53
their acceptable ranges constitute dosimetric criteria. For example, according to the RTOG-0321 dosimetric54
protocol [9], when treating prostate cancer, the VProstate100 (i.e. CTV coverage) should be greater than 90%55
of the prostate volume and the VRectum75 should be less than 1 cm
3. The objective of HDR brachytherapy56
planning is to determine a set of source dwell times that achieves the given dosimetric criteria.57
In iterative approaches to HDR brachytherapy planning such as in [11], suitable dose plans are computed58
by assigning penalties to dose points and finding a dose plan that minimizes the total penalty. For any given59
dose plan, dose points are penalized for receiving dose in an undesirable range. For example, a dose point in60
the CTV could be penalized for receiving less than Rx, and a dose point in the rectum could be penalized61
for receiving more than 75% Rx.62
The importance of individual dosimetric criterion are represented by the relative magnitude of the penalty63
weights. For instance, if the penalty for the CTV is three times that of the rectum, then achieving CTV64
coverage is more important to the physician than controlling the dose to the rectum. Penalties are useful65
when a standard set of dosimetric criteria is not known because it allows physicians to balance CTV coverage66
versus OAR exposure in a single objective.67
However, using penalties to achieve a prespecified set of dosimetric criteria can be difficult because penal-68
ties do not provide direct control over dosimetric indices. As a consequence, achieving dosimetric criteria69
with penalties becomes an iterative process. A set of penalties are hypothesized that will achieve dosimetric70
criteria; then a dose plan and dosimetry are computed. The process is repeated until a dose plan meeting71
all dosimetric criteria is achieved. Although a suitable dose plan can usually be found, it can take several72
iterations and is a time consuming process. Since standard dosimetric criteria are known for some cancer73
sites such as for prostate cancer, it is natural to utilize models that directly incorporate them.74
The model and heuristic presented in this study utilize optimization models from mathematical program-75
ming. In the following paragraphs we give a brief overview of these models, and describe how they relate to76
brachytherapy dose planning.77
A mixed integer program (MIP) is an optimization model of the form:78
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(MIP)Maximize cTx
Subject to :
Ax ≤ b,
xi ∈ R, i ∈ {1, ..., k},
xi ∈ Z, i ∈ {k + 1, ..., n},
where the known parameters c, A, and b are nx1, mxn, and mx1 matrices of real numbers, respectively, and79
x is an n x 1 vector of unknown variables. A feasible solution is an x that satisfies every constraint. The80
term cTx is called the objective function. The goal of a mixed integer program solver is to find an optimal81
solution – a feasible solution with the highest objective function value. If there are no variables in (MIP)82
that are restricted to be integers, then (MIP) reduces to a linear program (LP). LPs are efficiently solvable83
[12], even on a personal computer.84
Often, the mathematical structure of MIPs makes it difficult to find a provably optimal solution for them85
within a reasonable time [10]. As a consequence, fast heuristic, or suboptimal, approaches are required to86
make usable applications.87
Integer programs have been used to model prostate permanent-seed (PPI) brachytherapy and external88
beam dose planning [13, 14, 15, 16, 17, 18]. In particular, Ferris et al., 2002, used integer programs to89
constrain dosimetric indices. Our model extends these constraints to HDR brachytherapy which uses similar90
dosimetric indices. In many of these studies, extensive work was done to formulate customized algorithms to91
solve these models in a reasonable time. This study also presents a customized heuristic approach to compute92
fast but suboptimal solutions from our model. We present the model and heuristic in the following sections.93
3 Method and Materials94
3.1 Model Formulation95
We develop a mixed integer program for HDR brachytherapy planning. A description of subscripts, param-96
eters, and variables in this model are given for reference in Table 1.97
Dosimetric indices are estimated by sampling from a uniform grid of dose points that have been generated98
from evenly spaced anatomy image cross sections. The formulation of our model assumes the same set of99
dose points. The subscript ”s” denotes organs, and ”i” and ”j” denote dose points and dwell positions,100
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Term Description
s Subscript for organs.
i Subscript for dose points.
j Subscript for dwell positions.
Gs The set of dose points in organ s.
Psi The 3-D coordinates of dose point i in Gs.
Ns The number of dose points in Gs.
Tj The 3-D coordinates of dwell position j.
NT The number of dwell positions for this patient.
Dsij The dose rate from Tj to Psi.
tj Dwell time at Tj .
dsi Dose at Psi.
Rs Threshold dose for Gs.
Ms Maximum dose for Gs.
xsi Indicator variable for Psi.
vs Dosimetric index for Gs.
Ls Lower bound for vs.
Us Upper bound for vs.
Table 1: IPIP term definitions.
respectively. The set of dose points in an organ is Gs, and Psi is the 3 dimensional coordinate of a dose point101
in Gs. The number of dose points in an organ is Ns. Dwell positions are denoted by Tj , and the number of102
dwell positions is NT .103
The dose rate parameters, Dsij [cGy/s], are the dose received at Psi for every second the source remains104
at Tj . Rs [cGy] is the dose required for Psi to be counted in the dosimetric index for Gs. The maximum105
allowed dose for dose points in Gs is Ms [cGy]. Ls and Us are the upper and lower bounds for the dosimetric106
index for Gs, respectively.107
The optimization variables are the dwell times, tj [seconds], the dose at each dose point dsi [cGy], the108
dosimetric indices for each organ, vs, and the indicator variables, xsi [1]. The dwell times are continuous109
variables that represent the source time spent at Tj . The total dose received at Psi is the sum of the110
contributions from every dwell position, dsi =
∑NT
j=1Dsijtj . The indicator variables are binary variables that111
should have the following behavior:112
xsi =
 1 if dsi ≥ Rs0 otherwise
Finally, the dosimetric index for Gs is the sum of all the indicator variables, vs =
Ns∑
i=1
xsi.113
We dub the model Inverse Planning by Integer Program (IPIP). It is presented in its entirety below.114
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(IPIP )
Maximize v0
Subject to :
dsi =
NT∑
j=1
Dsijtj , ∀s, i ∈ Gs,(1)
Rsxsi ≤ dsi ≤ Rs + (Ms −Rs)xsi − , ∀s, i ∈ Gs,(2)
vs =
Ns∑
i=1
xsi, ∀i ∈ Gs,(3)
Ls ≤ Is ≤ Us ∀s,(4)
tj ≥ 0 ∀j,(5)
xsi ∈ {0, 1} ∀s, i ∈ Gs.(6)
115
116
The objective of IPIP is to maximize v0, CTV coverage. The first constraint (1) integrates the dose at117
Psi from every dwell position. The purpose of (2) and (6) is to enforce the relationship between dsi and118
xsi. For a given dose dsi at Psi, if xsi = 1, (2) reduces to Rs ≤ dsi ≤ Ms − , and if xsi = 0, it reduces to119
0 ≤ dsi ≤ Rs − . Conversely, if dsi ≥ Rs, then xsi = 1, and if dsi < Rs, then xsi = 0. Therefore, xsi = 1 if120
and only if dsi ≥ Rs, and the indicator variables behave as desired.121
The parameter  is a small number that is included so that the value of xsi has no ambiguity when dsi = Rs.122
More specifically, if dsi equals Rs, then 1 or 0 is valid for xsi even though it should take the value 1 according123
to our definition. For very small , (2) becomes an approximation to Rsxsi ≤ dsi < Rs+(Ms−Rs)xsi, which124
ensures that xsi = 1 when dsi = Rs. If this level of precision is not required, then  can be omitted from the125
formulation.126
Constraint (3) integrates the dosimetric indices over all the indicator variables. Constraint (4) enforces127
dosimetric criteria. Since dose points lie on a uniform grid, each dose point is representative of an equal organ128
volume. Therefore, constraining the amount of organ volume receiving Rs dose can be made equivalent to129
constraining the number dose points receiving Rs. For example if each dose point represents 0.1 cm
3 of organ130
volume, and no more than 1 cm3 of organ can receive over the threshold dose, then the number of dose points131
in the organ that can receive over the threshold dose is 10 dose points.132
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Constraint (5) restricts the dwell times to be non-negative and (6) constrains the indicator variables to133
be binary.134
IPIP is a direct approach to finding dose plans with dosimetric criteria. However, our initial tests showed135
that it could not compute an optimal (or feasible solution) reliably for reasonably sized instances, even given136
several hours. Therefore in the following section, we develop a fast heuristic method for computing feasibly137
solutions.138
3.2 IPIP Heuristic formulation139
The computational difficulty in solving IPIP comes from the binary variables, xsi, that make IPIP a MIP.140
We develop a heuristic to quickly determine values for the indicator variables in IPIP. This is accomplished141
by first relaxing IPIP using fewer and weaker constraints. The resulting optimization model is an LP, which142
can be solved quickly. The dose plan computed from this relaxation is analyzed, and based on this analysis,143
all xsi from OAR (which have a dose upper limit) are set to 1 or 0. A doseplan is computed from the model144
with the set indicator variables. This dose plan is feasible for all upperbound dosimetric constraints (i.e.145
vs ≤ Us), but not necessarily feasible for lowerbound constraints (i.e. Ls ≤ vs).146
First, the binary restriction for the indicator variables in IPIP is relaxed to allow all values between 0147
and 1 (i.e. the constraint xsi ∈ {0, 1} becomes 0 ≤ xsi ≤ 1). Also constraints on dosimetric index values148
are removed. The resulting optimization problem is the following linear program referred to as the heuristic149
relaxation (HR).150
(HR)Maximize
N0∑
i=1
x0i
Subject to :
NT∑
j=1
Dsijtj ≥ Rsx0i, ∀i ∈ G0,
NT∑
j=1
Dsijtj ≤Ms − , ∀s, i ∈ Gs,
tj ≥ 0 ∀j,
0 ≤ x0i ≤ 1, ∀i ∈ G0.
Since dosimetric indices are not constrained, the indicator variables that make up these dosimetric indices151
are omitted in HR. The dose at any dose point is only limited by the maximum dose, Ms. The indicator152
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variables for the CTV (i.e. x0i) are retained and maximized in the objective.153
In general, a dose plan computed from HR will not satisfy the dosimetric criteria for the OAR in IPIP154
(i.e. vs > Us). In IPIP, the value of the indicator variable xsi determines if the dose at Psi should be less155
than Rs (xsi = 0) or Ms (xsi = 1). Therefore, setting xsi to 0 or 1 is equivalent to setting the dose upper156
limit for Psi to Rs or Ms respectively. In the current solution to HR, all the OAR indicator variables have157
been set to 1, making the dose upper limit to these dose points Ms. The next step of this heuristic is to set158
all but Us of the OAR indicator variables to 0. Then, vs is guaranteed to be less than Us for these organs.159
In this heuristic, the Us dose points in Gs receiving the most dose retain a dose upper limit of Ms.160
The remaining dose points are restricted to receive less than Rs. This can be accomplished by adding the161
constraint
NT∑
j=1
Dsijtj ≤ Rs −  to the Ns − Us dose points in Gs that are receiving the least dose in the162
HR dose plan. The reason this allocation of indicator variables was chosen is as follows. The HR dose163
plan will have higher coverage than the IPIP optimal solution because it has fewer constraints. We impose164
additional constraints on HR so that it will be feasible for IPIP, and these additional constraints will reduce165
the coverage of the HR dose plan. Further restricting the coldest dose points will impact CTV coverage the166
least because they must be altered the least to be excluded from the dosimetric index for that organ. After167
these constraints are added, HR with the additional constraints is resolved as an LP.168
A common dosimetric criterion is for CTV coverage to be more than a certain percentage of the CTV.169
This is represented in IPIP by the constraint L0 ≤ v0. This constraint was removed in HR and is not170
enforced by the additional constraints added later on. As a consequence, meeting lower bound dosimetric171
index constraints is not guaranteed by this heuristic. However, usually the only dosimetric index with a172
lower bound constraint is for CTV coverage, and this dosimetric index is maximized the objective of HR.173
Therefore, if the upper bound constraints are not too stringent, this criterion is likely to be met or come174
close.175
Our IPIP heuristic is summarized as follows:176
(1) Solve HR.177
(2) For each Gs except the CTV, let Psi∗ denote the Ns − Us dose points receiving the least dose in Gs in178
the HR dose plan solution.179
(3) For every Psi ∈ Psi∗ add the constraint
NT∑
j=1
Dsijtj ≤ Rs −  to HR.180
(4) resolve updated HR to get dose plan.181
For the sake of brevity, we will not distinguish between IPIP and this heuristic for the remainder of the182
paper.183
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3.3 Patient Data Sets184
We applied IPIP retrospectively to 20 prostate cancer patient cases. These patients were chosen to have a185
wide range of prostate volumes ranging from 23 to 103 cm3. For these patients, the physician implanted 14186
to 18 catheters in the prostate with transrectal ultrasound (TRUS) guidance while the patient was under187
epidural anesthesia. Then Flexi-guide catheters (Best Industries, Inc., Flexi-needles, 283-25 (FL153-15NG)),188
which are 1.98-mm-diameter hollow plastic needles through which the radioactive source move, were inserted189
transperineally by following the tip of the catheter from the apex of the prostate to the base of the prostate190
using ultrasound and a stepper. A Foley catheter was inserted to help visualize the urethra.191
After catheter implantation, a treatment planning pelvic CT scan was obtained for each patient. Three-192
millimeter-thick CT slices were collected using a spiral CT. The CTV and OAR (urethra, rectum, and bladder)193
were contoured using the Nucletron Plato Version 14.2.6 (Nucletron B.V., Veenendaal, The Netherlands).194
The CTV included only the prostate and no margin was added. When segmenting the bladder and rectum,195
the outermost mucosa surface was contoured. The urethra was defined by the outer surface of the Foley196
catheter, and only the urethral volume within the CTV was contoured. The OAR were contoured on all CT197
slices containing the CTV and at least two additional slices above and below. Implanted catheters were also198
digitized.199
For the contoured anatomical structures, dose points were generated by sampling from a uniform grid200
with 2 mm spacing in the x-y direction and 3 mm spacing in the z direction. Dose points were also generated201
in the body tissue (space between organs) with 4 mm spacing in the x-y direction. For the 20 cases, the202
total number of dose points for IPIP ranged from 8860 to 25288. To reduce the computation required, every203
dose point more than 3.5 cm from the xy-centroid of the dwell positions were omitted in the optimization.204
However, they were included when computing the dosimetric indices. Our tests showed that removing these205
dose points had no effect on the dosimetric index values. The number of dose points after removing dose206
points ranged from 6144 to 15568.207
3.4 Dose rate calculations and clinical criteria208
The dose-rate contribution to a dose point from a source dwell position is a function of the distance between209
them. The dose-rate parameters were calculated as specified in the AAPM TG-43 dosimetry protocol [20].210
The radioactive material used in the source was 192Ir, and the prescription dose was 9.5 Gy.211
The clinical criteria used in this study can be found in Table 2. The specifications for the VProstate100 ,212
VUrethra125 , V
Rectum
75 , and V
Bladder
75 are defined by RTOG-0321 [9]. RTOG specifies that the V
Urethra
125 be much213
less than 1cm3. We interpreted this to mean less than 0.1cm3.214
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Index Requirement
VProstate100 ≥ 90%
VProstate150 ≤ 45%
VUrethra120 ≤ 0.1 cm3
VUrethra150 = 0 cm
3
VRectum75 ≤ 1 cm3
VRectum100 0 cm
3
VBladder75 ≤ 1 cm3
VBladder100 = 0 cm
3
VBody200 = 0 cm
3
Table 2: Dosimetric Criteria.
The VProstate150 is not explicitly constrained by the RTOG-0321 protocol. The V
Prostate
150 is restricted by the215
homogeneity index (HI) where:216
217
HI =
VProstate100 −VProstate150
VProstate100
.
It is generally preferred that HI ≥ 0.6; however, lower values of HI are acceptable if they allow for higher218
CTV coverage. For this study, we constrain HI to be greater than 50% to maintain some control over the219
VProstate150 while not being overly restrictive. Since we expect target coverage over 90%, this restriction on HI220
can be enforced with VProstate150 ≤ 45%.221
The restrictions that the VUrethra150 , V
Rectum
100 , V
Bladder
100 , and V
Body
200 be equal to 0 are not specified by RTOG222
but are considered preferable when possible at our clinic. The preference of the VBody200 comes from the desire223
to keep hot spots localized within the CTV.224
These dosimetric index constraints represent our dosimetric criteria. They are summarized in Table 2.225
The parameters used for IPIP to reflect these dosimetric criteria can be found in Table 3. The values226
of 8 and 83 for Us represent the number of dose points in 0.1 cm
3 and 1.0 cm3, respectively, based on our227
grid spacing. The value of Us for the V
Prostate
150 is 45% the number of dose points in the prostate. The dose228
to prostate dose points should be unrestricted so we have used an unrestrictively high number, 20000 cGy.229
We did this to avoid using infinity, which creates numerical problems with our optimization solver. The230
dosimetry in our results shows no dose points receiving this dose level for any patient.231
3.5 Method evaluation232
We used Matlab v. R2008b (Mathworks Inc.) to compute dose plans from IPIP. The linear programming233
optimization was done using the Matlab interface for the Mosek Optimization Toolbox v.5, a medium to234
large scale optimization package. All computations were performed on a personal computer with Intel(R)235
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Organ s Rs Ms Us
Prostate 0 950 20000 N0
Prostate 1 1425 20000 .45 N0
Urethra 2 1140 1425 8
Rectum 3 712 950 83
Bladder 4 712 950 83
Body 5 1900 1900 0
Table 3: IPIP Parameters
Approach
Dosimetric Index IPSA IPIP
VProstate100 100% 100%
VProstate150 100% 100%
VUrethra125 85% 100%
VUrethra150 50% 100%
VRectum75 80% 100%
VRectum100 55% 100%
VBladder75 65% 100%
VBladder100 100% 100%
VBody200 5% 100%
HI 100% 100%
All Requirements 0% 100%
Table 4: IPSA and IPIP compliance with dosimetric criteria. Percentage of patient dose plans (out of 20)
that complied with each constraint for each approach. Note that the dosimetric constraints supplied were
hard constraints, meaning even the slightest deviation from the limit is considered a failure.
CoreTM2 Duo CPU 1.67 GHz processor, 3 Gib RAM, and the Windows 32-bit operating system. We record236
the compliance of IP2H dose plans with our dosimetric criteria and the running time.237
4 Results238
IPIP satisfied all our dosimetric requirements on the first iteration. For comparison, we also computed239
dose plans from Inverse Planning Simulated Annealing (IPSA), a clinically deployed dose planning system240
used at our clinic. All computational parameters for IPSA were the same as in Alterovitz, 2006 [19]. No241
computational parameters from IPSA were manipulated after the first iteration.242
The compliance rate (out of 20 patients) for each individual dose objective is summarized in Table 4.243
Note that our constraints on dosimetric indices are hard constraints so even the slightest deviation from the244
requirement is considered a failure. The average CTV coverage from IPIP was 95%.245
On average, IPIP computed a dose plan within 30.1 seconds. The maximum runtime was 86 seconds. Our246
IPIP heuristic is made up of (1) solving a linear program, (2) sorting doses within each OAR, and (3) solving247
another linear program. Each one of these steps is polynomial time solvable, meaning that the number of248
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Dosimetric Index Value
VProstate100 78%
VProstate150 33%
VUrethra125 0.01cm
3
VRectum75 0 cm
3
VBladder75 0 cm
3
Table 5: Set of dosimetric criteria that cannot be met with IPIP. The VRectum75 and V
Bladder
75 were required to
be 0. For this case, CTV coverage was only 78% which does not meet our 90% requirement. Less stringent
dosimetric criteria must be given in the next iteration.
Dosimetry Dosimetric Criteria 1 Dosimetric Criteria 2
VProstate100 96% 91%
VProstate150 33% 30%
VUrethra125 0.01cm
3 0 cm3
VRectum75 0.92 cm
3 0.45 cm3
VBladder75 0.95 cm
3 0.44 cm3
Table 6: Comparison of different dosimetric criteria for a single patient. For Dosimetric Criteria 1, dosimetric
criteria was the same as in our main experiment. For Dosimetric Criteria 2, the VRectum75 and V
Bladder
75 are
restricted to be less than 0.5 cm3, which is more stringent. By restricting the VRectum75 and V
Bladder
75 , CTV
coverage drops by 5% but with large reduction to OAR exposure.
computations grows slowly (i.e. as a polynomial) with respect to the size of the input. As a consequence,249
the runtime performance of our IPIP heuristic is reliable for a more general audience of patients given that250
they have a similar number of dose points.251
For comparison, IPSA computed a dose plan within 5 seconds on average, with a maximum runtime252
of 9 seconds. However, IPSA would have required further iterations to achieve dosimetric criteria. These253
additional iterations are not included in the running time results for IPSA.254
We also conducted side tests to demonstrate cases in which IPIP does not behave as desired. First255
we showed a set of dosimetric criteria that cannot be met with IPIP by insisting that the VRectum75 , and256
VRectum75 be 0 cm
3. Otherwise, dosimetric criteria were the same. The results for a single patient are shown257
in Table 5. CTV coverage, which is lower bound constrained, is only 78% which does not meet the 90%258
requirement. However, all other criteria are fulfilled. In this case, additional iterations would be required259
using less stringent dosimetric criteria.260
Second, we showed a case where a dose plan computed from IPIP complies with dosimetric criteria but261
may not be what the physician desires. We computed two dose plans from IPIP using different sets of262
dosimetric criteria. The first dosimetric criteria set was the same that was used in our main experiment.263
The second dosimetric criteria set was more stringent with VRectum75 and V
Bladder
75 less than 0.5 cm
3. All other264
dosimetric criteria were the same as for the main experiment. The results are summarized in Table 6.265
CTV coverage for the first dosimetric criteria is 96%. To achieve this coverage, almost all of the dose266
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allowance to the rectum and bladder are utilized (i.e. VRectum75 and V
Bladder
75 is close to 1 cm
3). With the267
second dosimetric criteria, CTV coverage drops to 91%, but the overdosed volume to the rectum and bladder268
is cut in half.269
Since the objective of IPIP is to maximize coverage within limits to OAR dose, IPIP will tend to utilize270
all of the OAR dose available to it. More specifically, IPIP will make large increases to OAR dose, within271
its limits, even to make only small improvements to CTV coverage. In this case, the drop in CTV coverage272
(5%) between the two dose plans is worth considering, but a physician may still prefer the second dose plan.273
However, determining the second dose plan cannot be accomplished without iterating through alternative274
dosimetric criteria.275
5 Conclusion276
IPIP is a new approach that is more intuitive for physicians and less reliant on manual fine tuning. IPIP277
allows physicians to directly specify desired dosimetric indices, rather than system-specific computational278
parameters. Our results demonstrate that IPIP quickly generates dosimetry plans that are consistent with279
RTOG-0321 standard dosimetric criteria. Further study is required to determine if IPIP can produce similar280
performance for a more general group of patients and dosimetric criteria, including other cancer sites such281
as GYN.282
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